Clinicians throughout the European Union may now treat their patients suffering from acute and chronic pain or spasticity with a highly portable electromyographic (EMG [FREE Stock Trend Analysis]) precision device from Intronix Technologies can help target and treat unseen sources of pain with unprecedented precision. The newly approved Myoguide battery-powered handheld provides superior injection site targeting through its ability to detect and display the EMG signals characteristically emitted by these hidden pain sources. Intronix officials will demonstrate the latest version of Myoguide, also featuring new software and other improvements, at MEDICA 2011, the world’s largest annual medical trade fair, November 16-19 in Düsseldorf, Germany. Intronix will be exhibiting in Hall 16 as part of the Ontario, Canada pavilion.
